Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: A retrospective analysis with follow-up for 12 years

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2039-2045

  Paidpally, Vasavi ^a   Tahari, Abdel K ^a   Lam, Stella ^a   Alluri, Krishna ^a   Marur, Shanthi ^a   Koch, Wayne ^a   Wahl, Richard L ^a   Subramaniam, Rathan M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Follow up; Head and neck; Oncology; PET CT; Squamous cell cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PET-CT SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SECOND CANCER; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; UNCERTAINTY; WART VIRUS; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; HEAD AND NECK TUMOR; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; SURVIVAL; TIME; FOLLOW-UP; HEAD AND NECK; ONCOLOGY; PET/CT;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS, SQUAMOUS CELL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

FOLLOW-UP; HEAD AND NECK; ONCOLOGY; PET/CT; SQUAMOUS CELL CANCER;

EID: 84893380165     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.121285     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Davison JM, Ozonoff A, Imsande HM, Grillone GA, Subramaniam RM. Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. Radiology. 2010;255:578-585.
3. Imsande HM, Davison JM, Truong MT, et al. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. AJR. 2011;197:976-980.
4. Dibble EH, Lara Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709-715.
5. Paidpally V, Chirindel A, Lam S, Agrawal N, Quon H, Subramaniam RM. FDGPET/ CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med. 2012;4:633-647.
6. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083-2095.
7. Ritoe SC, Krabbe PF, Kaanders JH, van den Hoogen FJ, Verbeek AL, Marres HA. Value of routine follow-up for patients cured of laryngeal carcinoma. Cancer. 2004;101:1382-1389.
8. Pfister DG, Ang KK, Brizel DM, et al. Head and neck cancers. J Natl Compr Canc Netw. 2011;9:596-650.
9. Subramaniam RM, Truong M, Peller P, Sakai O, Mercier G. Fluorodeoxyglucose- positron-emission tomography imaging of head and neck squamous cell cancer. Am J Neuroradiol. 2010;31:598-604.
10. Jackson T, Chung MK, Mercier G, Ozonoff A, Subramaniam RM. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. Nucl Med Commun. 2012;33:305-312.
11. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009;50:24-29.
12. Minn H, Lapela M, Klemi P, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907-1911.
13. Zhang B, Li X, Lu X. Standardized uptake value is of prognostic value for outcome in head and neck squamous cell carcinoma. Acta Otolaryngol. 2010;130:756-762.
14. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.
15. Torizuka T, Tanizaki Y, Kanno T, et al. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR. 2009;192:W156-W160.
16. Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:1085-1093.
17. Connell CA, Corry J, Milner A, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;29:986-995.
18. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-adjusted [18F]fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009;27:2509-2515.
19. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer. 2009;115:4586-4594.
20. Yao M, Graham MM, Hoffman HT, et al. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2004;59:1001-1010.
21. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199-4208.
22. Beswick DM, Gooding WE, Johnson JT. Branstetter BF. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/ computed tomography monitoring. Laryngoscope. 2012;122:1512-1517.
23. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008;33:210-222.
24. Zhang I. Branstetter BF, Beswick DM, Maxwell JH, Gooding WE, Ferris RL. The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2011;137:1106-1111.
25. Sherriff JM, Ogunremi B, Colley S, Sanghera P, Hartley A. The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy. Br J Radiol. 2012;85:e1120-e1126.
26. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer: a long-term outcome report. Int J Radiat Oncol Biol Phys. 2009;74:9-14.